However, the absence of definitive evidence does not imply evidence of no effect: these areas remain open to research
Future research might look at patients who have features of both EGID and IBD (overlap colitis) to see if they represent a distinct endotype characterized by eosinophil dysfunction
The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increasing global obesity rates, limitations of traditional antidiabetic drugs, clinical success of glp-1 receptor agonists, growing physician confidence in injectable therapies
Find out if youre eligible for Microdose GLP-1 Rx What is your weight loss goal
Read on to find out more
Meanwhile, tirzepatide participants lost body weight by 16%, 21.4%, and 22.5% on 5 mg, 10 mg, and 15 mg (once weekly injections), respectively, after 72 weeks